Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
DRUG: Tislelizumab
R0 resection rate, 5 months
Progression-free survival (PFS), 18 months|Disease control rate (DCR), 5 months|Objective response rate (ORR), 5 months|Overall survival (OS), 24 months|Improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0), 24 months
This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.